Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-1165
Full Text
Open PDFAbstract
Available in full text
Date
February 15, 2008
Authors
Publisher
American Association for Cancer Research (AACR)